vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Natural Grocers by Vitamin Cottage, Inc.（NGVC）财务数据对比。点击上方公司名可切换其他公司
Natural Grocers by Vitamin Cottage, Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.8倍（$335.6M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 3.4%，领先10.0%），Natural Grocers by Vitamin Cottage, Inc.同比增速更快（1.6% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $11.6M），过去两年Natural Grocers by Vitamin Cottage, Inc.的营收复合增速更高（4.4% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Natural Grocers by Vitamin Cottage, Inc.是美国本土的特色零售连锁企业，主营认证有机食品、膳食补充剂、天然个护及环保家居类产品，面向健康意识较强的消费群体，门店覆盖美国多州，执行严格品控标准，拒绝售卖含人工添加剂的商品。
AMPH vs NGVC — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $335.6M |
| 净利润 | $24.4M | $11.3M |
| 毛利率 | 46.8% | 29.5% |
| 营业利润率 | 19.4% | 4.4% |
| 净利率 | 13.3% | 3.4% |
| 营收同比 | -1.8% | 1.6% |
| 净利润同比 | -35.7% | 14.0% |
| 每股收益（稀释后） | $0.51 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $183.1M | $335.6M | ||
| Q3 25 | $191.8M | $336.1M | ||
| Q2 25 | $174.4M | $328.7M | ||
| Q1 25 | $170.5M | $335.8M | ||
| Q4 24 | $186.5M | $330.2M | ||
| Q3 24 | $191.2M | $322.7M | ||
| Q2 24 | $182.4M | $309.1M | ||
| Q1 24 | $171.8M | $308.1M |
| Q4 25 | $24.4M | $11.3M | ||
| Q3 25 | $17.4M | $11.8M | ||
| Q2 25 | $31.0M | $11.6M | ||
| Q1 25 | $25.3M | $13.1M | ||
| Q4 24 | $38.0M | $9.9M | ||
| Q3 24 | $40.4M | $9.0M | ||
| Q2 24 | $37.9M | $9.2M | ||
| Q1 24 | $43.2M | $8.0M |
| Q4 25 | 46.8% | 29.5% | ||
| Q3 25 | 51.4% | 29.5% | ||
| Q2 25 | 49.6% | 29.9% | ||
| Q1 25 | 50.0% | 30.3% | ||
| Q4 24 | 46.5% | 29.9% | ||
| Q3 24 | 53.3% | 29.6% | ||
| Q2 24 | 52.2% | 29.2% | ||
| Q1 24 | 52.4% | 29.3% |
| Q4 25 | 19.4% | 4.4% | ||
| Q3 25 | 13.2% | 4.6% | ||
| Q2 25 | 24.2% | 4.7% | ||
| Q1 25 | 21.9% | 5.2% | ||
| Q4 24 | 24.2% | 4.0% | ||
| Q3 24 | 29.8% | 3.7% | ||
| Q2 24 | 30.3% | 4.2% | ||
| Q1 24 | 27.9% | 3.7% |
| Q4 25 | 13.3% | 3.4% | ||
| Q3 25 | 9.0% | 3.5% | ||
| Q2 25 | 17.8% | 3.5% | ||
| Q1 25 | 14.8% | 3.9% | ||
| Q4 24 | 20.4% | 3.0% | ||
| Q3 24 | 21.1% | 2.8% | ||
| Q2 24 | 20.8% | 3.0% | ||
| Q1 24 | 25.1% | 2.6% |
| Q4 25 | $0.51 | $0.49 | ||
| Q3 25 | $0.37 | $0.51 | ||
| Q2 25 | $0.64 | $0.50 | ||
| Q1 25 | $0.51 | $0.56 | ||
| Q4 24 | $0.74 | $0.43 | ||
| Q3 24 | $0.78 | $0.38 | ||
| Q2 24 | $0.73 | $0.40 | ||
| Q1 24 | $0.81 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $23.2M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $220.0M |
| 总资产 | $1.6B | $668.6M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
| Q4 25 | $282.8M | $23.2M | ||
| Q3 25 | $276.2M | $17.1M | ||
| Q2 25 | $231.8M | $13.2M | ||
| Q1 25 | $236.9M | $21.2M | ||
| Q4 24 | $221.6M | $6.3M | ||
| Q3 24 | $250.5M | $8.9M | ||
| Q2 24 | $217.8M | $13.9M | ||
| Q1 24 | $289.6M | $11.0M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $220.0M | ||
| Q3 25 | $776.7M | $212.4M | ||
| Q2 25 | $757.5M | $202.5M | ||
| Q1 25 | $751.3M | $193.0M | ||
| Q4 24 | $732.3M | $181.9M | ||
| Q3 24 | $727.7M | $174.3M | ||
| Q2 24 | $713.3M | $167.8M | ||
| Q1 24 | $672.4M | $160.0M |
| Q4 25 | $1.6B | $668.6M | ||
| Q3 25 | $1.7B | $670.5M | ||
| Q2 25 | $1.6B | $659.0M | ||
| Q1 25 | $1.6B | $664.6M | ||
| Q4 24 | $1.6B | $648.9M | ||
| Q3 24 | $1.5B | $655.5M | ||
| Q2 24 | $1.5B | $654.4M | ||
| Q1 24 | $1.6B | $656.6M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $21.1M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $11.6M |
| 自由现金流率自由现金流/营收 | 13.4% | 3.4% |
| 资本支出强度资本支出/营收 | 4.5% | 2.9% |
| 现金转化率经营现金流/净利润 | 1.35× | 1.86× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $42.6M |
8季度趋势，按日历期对齐
| Q4 25 | $32.9M | $21.1M | ||
| Q3 25 | $52.6M | $15.6M | ||
| Q2 25 | $35.6M | $2.9M | ||
| Q1 25 | $35.1M | $34.1M | ||
| Q4 24 | $29.0M | $2.7M | ||
| Q3 24 | $60.0M | $24.5M | ||
| Q2 24 | $69.1M | $12.4M | ||
| Q1 24 | $55.3M | $20.2M |
| Q4 25 | $24.6M | $11.6M | ||
| Q3 25 | $47.2M | $7.5M | ||
| Q2 25 | $25.0M | $-4.2M | ||
| Q1 25 | $24.4M | $27.6M | ||
| Q4 24 | $16.6M | $-6.9M | ||
| Q3 24 | $46.2M | $18.0M | ||
| Q2 24 | $63.1M | $3.6M | ||
| Q1 24 | $46.5M | $9.8M |
| Q4 25 | 13.4% | 3.4% | ||
| Q3 25 | 24.6% | 2.2% | ||
| Q2 25 | 14.3% | -1.3% | ||
| Q1 25 | 14.3% | 8.2% | ||
| Q4 24 | 8.9% | -2.1% | ||
| Q3 24 | 24.1% | 5.6% | ||
| Q2 24 | 34.6% | 1.2% | ||
| Q1 24 | 27.1% | 3.2% |
| Q4 25 | 4.5% | 2.9% | ||
| Q3 25 | 2.8% | 2.4% | ||
| Q2 25 | 6.1% | 2.2% | ||
| Q1 25 | 6.3% | 1.9% | ||
| Q4 24 | 6.7% | 2.9% | ||
| Q3 24 | 7.2% | 2.0% | ||
| Q2 24 | 3.3% | 2.9% | ||
| Q1 24 | 5.1% | 3.4% |
| Q4 25 | 1.35× | 1.86× | ||
| Q3 25 | 3.03× | 1.32× | ||
| Q2 25 | 1.15× | 0.25× | ||
| Q1 25 | 1.39× | 2.60× | ||
| Q4 24 | 0.76× | 0.27× | ||
| Q3 24 | 1.48× | 2.72× | ||
| Q2 24 | 1.82× | 1.35× | ||
| Q1 24 | 1.28× | 2.54× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
NGVC
| Grocery | $243.8M | 73% |
| Dietary Supplements | $60.7M | 18% |
| Manufactured Product Other | $31.0M | 9% |
